Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2026
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/apt.70613 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia Paul Y. Kwo Laura E. Telep Lai San Hong Ching Yi Chuo Betty Chiang Sarjita D. Naik Catherine T. Frenette Amanda W. Singer Anand P. Chokkalingam Robert J. Wong Leland J. Yee Camilla S. Graham Alimentary Pharmacology & Therapeutics ABSTRACT Background The relationship between hepatitis B virus low‐level viraemia (HBV‐LLV; HBV DNA ≤ 2000 IU/mL) and the risk of liver‐related events is unclear. Aim To evaluate the relationship between HBV‐LLV and subsequent liver‐related outcomes in patients with chronic HBV. Methods Using Optum's deidentified Clinformatics Data Mart Database, propensity score–matched cohorts of adults (aged ≥ 18 years) with chronic HBV‐LLV vs. controls without evidence of chronic HBV were identified. Cox proportional‐hazards models were used to estimate the risk of compensated cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), liver transplant, and a composite outcome of these four liver‐related events among people with HBV‐LLV vs. those without HBV. Incidence rates per 100 person‐years and corresponding Poisson 95% CIs were calculated for each cohort. Results Demographic and clinical characteristics were similar between cohorts. The risk of cirrhosis, decompensation, HCC, and the composite outcome was significantly higher for patients with HBV‐LLV than for individuals without HBV. Elevated liver disease risk remained in a sensitivity analysis of a subgroup with no nucleos(t)ide analogue treatment or HBV DNA > 2000 IU/mL during follow‐up. Elevated risk of cirrhosis and composite outcomes in patients with HBV‐LLV was confirmed in a second US dataset (HealthVerity Marketplace). Conclusions In this analysis of US administrative claims data, individuals with HBV‐LLV had a significantly increased risk of liver‐related events compared with those without evidence of HBV. Additional research is needed to identify risk stratification and mitigation strategies, including earlier antiviral treatment. 10.1111/apt.70613 http://creativecommons.org/licenses/by-nc-nd/4.0/